Quick Answer
Heart failure delivers 2 to 3 NEET PG questions per paper across Cardiology, Internal Medicine, and Pharmacology. The high-yield framework:
- Classify by EF — HFrEF (EF at or below 40 percent), HFmrEF (41 to 49 percent), HFpEF (50 percent and above with elevated BNP plus diastolic dysfunction).
- Stage and severity — AHA/ACC stages A to D for risk progression; NYHA I to IV for current symptoms.
- GDMT four pillars — ARNI, beta-blocker, MRA, SGLT2 inhibitor. All four reduce mortality in HFrEF.
- Acute decompensation — IV loop diuretic first; nitrates if hypertensive; NIV for pulmonary edema; inotropes only in cardiogenic shock.
- Devices — ICD for primary prevention if EF at or below 35 percent on GDMT; CRT if QRS at or above 150 ms with LBBB.
- BNP/NT-proBNP — rule-out cutoffs are BNP under 100 and NT-proBNP under 300 pg/mL.
Heart failure is the final common pathway of nearly every cardiovascular disease, which is exactly why NEET PG examiners reach for it so often. The 2022 AHA/ACC/HFSA guideline and the 2023 ESC focused update reshaped therapy with the four-pillar approach, and Indian clinical practice has adapted rapidly — though access to ARNI and SGLT2 inhibitors still varies sharply between metro tertiary centres and district hospitals.
This NEETPGAI deep dive walks through classification, the diagnostic algorithm, the modern GDMT sequence, acute decompensation management, device therapy, and the high-yield traps that turn up as drag-and-drop or sequence-of-management questions. Pair it with the Medicine subject hub and the antiplatelet and anticoagulant pharmacology guide for full cardiology fluency.
Classification of heart failure
Modern heart failure is classified along three axes — ejection fraction, AHA/ACC stage, and NYHA functional class — and NEET PG vignettes routinely combine all three.
Ejection fraction categories (2022 AHA/ACC)
| Category | LVEF | Key feature |
|---|
| HFrEF | At or below 40 percent | Reduced systolic function; full GDMT benefits |
| HFmrEF | 41 to 49 percent | Mildly reduced; treat as HFrEF for guideline-directed therapy |
| HFpEF | 50 percent or above | Preserved EF plus elevated BNP and diastolic dysfunction on echo |
| HFimpEF | Previously HFrEF, now above 40 percent | Continue GDMT — improvement does not equal cure |
AHA/ACC stages A to D
- Stage A — at risk (hypertension, diabetes, CAD) without structural disease or symptoms.
- Stage B — structural disease (LVH, prior MI, low EF) without symptoms.
- Stage C — symptomatic heart failure.
- Stage D — refractory; needs advanced therapies (transplant, LVAD, palliation).
NYHA functional class
- Class I — no limitation of activity.
- Class II — slight limitation; comfortable at rest.
- Class III — marked limitation; symptoms with less-than-ordinary activity.
- Class IV — symptoms at rest.
NYHA class drives device decisions (CRT requires class II to ambulatory IV) and prognosis; AHA stage is unidirectional (you cannot regress from C to B even if symptoms resolve).
Clinical features and bedside profiles
The Forrester and Stevenson 2x2 profiles are still tested. Stevenson uses wet vs dry (congestion) and warm vs cold (perfusion):
- Warm and dry — compensated; outpatient management.
- Warm and wet — most common admission profile; needs diuresis.
- Cold and wet — cardiogenic shock with congestion; diuretic plus inotrope or vasodilator.
- Cold and dry — low output without congestion; cautious fluid challenge then inotrope.
Classic exam clues include orthopnea (specificity above 75 percent), paroxysmal nocturnal dyspnea, elevated JVP (most specific bedside sign), S3 gallop (the single best bedside sign for elevated filling pressures in adults), bibasal crepitations, and bilateral pitting edema. Cheyne-Stokes respiration during sleep is a high-yield clue in advanced HFrEF.
Diagnostic workup
Natriuretic peptides
BNP and NT-proBNP are the cornerstone biomarkers. Examiner-favourite cutoffs:
| Test | Rule-out | Suggestive | Strongly positive |
|---|
| BNP | Under 100 pg/mL | 100 to 400 | Above 400 pg/mL |
| NT-proBNP (age 50 to 75) | Under 300 | 300 to 900 | Above 900 pg/mL |
| NT-proBNP (under 50) | Under 300 | 300 to 450 | Above 450 pg/mL |
| NT-proBNP (above 75) | Under 300 | 300 to 1800 | Above 1800 pg/mL |
Levels are lower in obesity (false-negative) and higher in renal failure, atrial fibrillation, sepsis, and pulmonary embolism (false-positive).
Other essential tests
- ECG — assess rhythm, ischaemia, LVH, LBBB; a normal ECG has 98 percent negative predictive value for systolic dysfunction.
- Echocardiography — defines EF, chamber size, diastolic function, valves, pericardium. The single most useful test.
- Chest X-ray — cardiomegaly (CT ratio above 0.5), upper-lobe diversion, Kerley B lines, pleural effusion (right more than left in HF).
- Cardiac MRI — gold standard for EF; useful for infiltrative diseases (amyloid, sarcoid, hemochromatosis).
- Coronary angiography — for new-onset HF when CAD is suspected.
Guideline-directed medical therapy (GDMT) — the four pillars
The 2022 AHA/ACC and 2023 ESC updates simplified HFrEF therapy into four pillars, all started early and titrated together rather than sequentially.
Pillar 1 — RAAS blockade (ARNI preferred)
- Sacubitril-valsartan (ARNI) — preferred first-line; PARADIGM-HF showed 20 percent mortality reduction vs enalapril. Start 49/51 mg BD, titrate to 97/103 mg BD over 4 to 6 weeks.
- Wash-out — stop ACE inhibitor for 36 hours before starting ARNI to avoid angioedema.
- ACE inhibitor (enalapril, ramipril, lisinopril) — alternative if ARNI unavailable or unaffordable; the most common Indian district-hospital choice.
- ARB (losartan, valsartan, candesartan) — if ACEi-induced cough.
- Avoid combining ACEi with ARB (ONTARGET — increased adverse events without benefit).
Pillar 2 — Beta-blockers
Only three evidence-based beta-blockers reduce mortality in HFrEF: carvedilol, metoprolol succinate (extended release), bisoprolol. Start at low dose only when euvolemic; never initiate in acute decompensation. Titrate every 2 weeks. Atenolol and short-acting metoprolol tartrate are NOT evidence-based in HF.
Pillar 3 — Mineralocorticoid receptor antagonists (MRA)
Spironolactone (RALES) or eplerenone (EPHESUS, EMPHASIS-HF). Start 12.5 to 25 mg daily after confirming potassium under 5 mEq/L and eGFR above 30 mL/min. Monitor potassium and creatinine at week 1, week 4, then quarterly. Eplerenone preferred when gynecomastia is troublesome (selective receptor activity).
Pillar 4 — SGLT2 inhibitors
Dapagliflozin (DAPA-HF) and empagliflozin (EMPEROR-Reduced and EMPEROR-Preserved) reduce HF hospitalisation and mortality across the entire EF spectrum, including HFpEF — the only class with a Class I HFpEF indication as of 2023 ESC. Start 10 mg once daily; works regardless of diabetes status. Watch for euglycemic DKA, mycotic genital infections, and volume depletion.
Adjunctive therapy
- Loop diuretics — furosemide, torsemide, bumetanide. Symptomatic relief only; no mortality benefit. Use the lowest dose that maintains euvolemia.
- Hydralazine plus isosorbide dinitrate — Class I in self-identified Black patients (A-HeFT) or when ACEi/ARB/ARNI cannot be used.
- Ivabradine — for sinus rhythm with HR above 70 bpm despite max-tolerated beta-blocker (SHIFT trial).
- Vericiguat — soluble guanylate cyclase stimulator for worsening HFrEF on full GDMT (VICTORIA).
- Digoxin — symptom relief and HF hospitalisation reduction (DIG trial); no mortality benefit. Useful in AF with rapid ventricular response when beta-blocker is insufficient.
- Iron repletion — IV ferric carboxymaltose if ferritin under 100 or 100 to 299 with TSAT under 20 percent (AFFIRM-AHF).
Acute decompensated heart failure (ADHF)
ADHF is the commonest internal-medicine admission diagnosis above age 65 and a near-certain NEET PG vignette.
Initial assessment (within 30 minutes)
Stevenson profile, vitals, oxygen saturation, ECG, troponin, BNP/NT-proBNP, basic metabolic panel, lactate, chest X-ray, bedside echo when available.
Management ladder
- Oxygen if SpO2 below 90 percent. Avoid routine high-flow oxygen in normoxic patients.
- Non-invasive ventilation (CPAP or BiPAP) for cardiogenic pulmonary edema with respiratory distress — reduces intubation and mortality.
- IV loop diuretic — furosemide 40 to 80 mg IV bolus, or 2.5 times the home oral dose, given as bolus or continuous infusion (DOSE trial showed similar efficacy).
- Vasodilators — nitroglycerin infusion if systolic BP above 110 mmHg; sodium nitroprusside for severe hypertensive HF (caution in renal failure due to thiocyanate toxicity).
- Inotropes — dobutamine or milrinone only in cardiogenic shock with end-organ hypoperfusion (cold and wet or cold and dry). Avoid routine inotrope use; INTROPE-HF and other registries show increased mortality.
- Vasopressors — norepinephrine for cardiogenic shock with hypotension despite inotrope.
- Mechanical support — IABP, Impella, or VA-ECMO in refractory cardiogenic shock; LVAD as bridge to transplant.
Diuretic resistance is treated by sequential nephron blockade — add thiazide (metolazone or hydrochlorothiazide) 30 minutes before the loop diuretic.
Device therapy
Implantable cardioverter-defibrillator (ICD)
- Primary prevention — ischaemic or non-ischaemic cardiomyopathy with EF at or below 35 percent, NYHA II to III, on at least 3 months of GDMT, life expectancy above 1 year. For ischaemic, wait at least 40 days post-MI and 90 days post-revascularization.
- Secondary prevention — survivor of cardiac arrest, sustained VT with hemodynamic compromise.
Cardiac resynchronisation therapy (CRT)
CRT delivers biventricular pacing to correct dyssynchrony.
| Indication strength | Criteria |
|---|
| Class I (strongest) | EF at or below 35 percent, sinus rhythm, LBBB, QRS at or above 150 ms, NYHA II to ambulatory IV on GDMT |
| Class IIa | Same as above with QRS 120 to 149 ms LBBB, or QRS at or above 150 ms non-LBBB |
| Class IIb | EF at or below 35 percent with AF and need for ventricular pacing above 40 percent |
CRT is strongest in LBBB with wider QRS and in women.
NEET PG MCQ traps
- HFpEF therapy 2026 update — SGLT2 inhibitors are now Class I for HFpEF; no other drug class has a Class I indication in HFpEF.
- ARNI wash-out — 36 hours after stopping ACEi to avoid angioedema. Stopping the same day is the wrong-answer distractor.
- Beta-blocker initiation timing — never start during acute decompensation; wait until euvolemic and off IV diuretics. The trap stem mentions a wet patient on day 1 of admission.
- Inotrope misuse — routine dobutamine in non-shocked ADHF increases mortality. Reserve for cardiogenic shock.
- Acute MR with flash pulmonary edema — sudden pulmonary edema with new systolic murmur after MI suggests papillary muscle rupture or acute MR — needs emergency surgery, not just diuretics.
- High-output failure causes — anaemia, thyrotoxicosis, beriberi, AV fistula, Paget disease, pregnancy. EF is normal or high.
- RV infarction preload management — inferior STEMI with hypotension; avoid nitrates and diuretics; give IV fluids first.
- Digoxin toxicity — yellow-green vision (xanthopsia), nausea, arrhythmia (bidirectional VT pathognomonic). Treat with digibind for severe toxicity.
- Spironolactone-induced gynecomastia — switch to eplerenone.
- Iron deficiency without anaemia — still benefits from IV iron in HFrEF.
Recent updates and Indian context
- 2023 ESC focused update — SGLT2 inhibitors elevated to Class I across HFrEF, HFmrEF, and HFpEF.
- 2022 AHA/ACC guideline — formal four-pillar terminology; HFimpEF added as a new category.
- STRONG-HF trial (2022) — high-intensity GDMT titration during admission cut 180-day events by 34 percent.
- DELIVER trial (2022) — confirmed dapagliflozin benefit in HFpEF.
- Indian access reality — ARNI is approximately 12 to 15 times costlier than enalapril; SGLT2 inhibitors are now off-patent (dapagliflozin generics available) and increasingly accessible. NMC-affiliated tertiary centres should still attempt full GDMT, while district hospitals often default to ACEi plus beta-blocker plus MRA plus generic dapagliflozin.
- Rheumatic heart disease remains a leading HF cause in India — always look for mitral stenosis or regurgitation in young Indian women presenting with HF, a frequent FMGE and NEET PG vignette.
- Tropical considerations — endomyocardial fibrosis, peripartum cardiomyopathy (especially in eastern India), and chronic anaemia from nutritional deficiency are India-specific HF aetiologies tested in NEXT-style questions.
Frequently asked questions
What are the four pillars of GDMT in HFrEF?
The four pillars are an ARNI (sacubitril-valsartan) or ACE inhibitor/ARB if ARNI unavailable, an evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and an SGLT2 inhibitor (dapagliflozin or empagliflozin). All four should be initiated and titrated as early as tolerated to reduce mortality.
How do you differentiate HFrEF, HFmrEF, and HFpEF?
HFrEF is heart failure with ejection fraction at or below 40 percent. HFmrEF (mildly reduced) is EF 41 to 49 percent. HFpEF (preserved) is EF 50 percent or above with structural or functional cardiac abnormality and elevated natriuretic peptides. Diagnosis of HFpEF requires confirmation by elevated BNP plus echo evidence of diastolic dysfunction.
What BNP and NT-proBNP cutoffs rule in or rule out heart failure?
BNP below 100 pg/mL or NT-proBNP below 300 pg/mL effectively rules out acute heart failure. BNP above 400 pg/mL or NT-proBNP above 900 pg/mL (age 50 to 75) strongly supports the diagnosis. Age-adjusted NT-proBNP cutoffs are 450 (under 50), 900 (50 to 75), and 1800 pg/mL (above 75).
When is CRT indicated in heart failure?
Cardiac resynchronisation therapy is indicated for HFrEF with EF at or below 35 percent, sinus rhythm, QRS at or above 150 ms with left bundle branch block morphology, and NYHA class II to ambulatory IV symptoms despite three months of optimal GDMT. The benefit is greatest in LBBB with QRS above 150 ms.
What is the first-line treatment of acute decompensated heart failure?
Intravenous loop diuretic (furosemide 40 to 80 mg IV bolus or 2.5 times the home oral dose) is first-line. Add nitrates if systolic BP is above 110 mmHg and pulmonary congestion is severe. Non-invasive ventilation reduces intubation in cardiogenic pulmonary edema. Inotropes are reserved for cardiogenic shock with end-organ hypoperfusion.
This content is for educational purposes for NEET PG exam preparation. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical information has been reviewed by qualified medical professionals.
Written by: NEETPGAI Editorial Team
Reviewed by: Pending SME Review
Last reviewed: May 2026
